Pharmaceutical - Xolair

Filter

Current filters:

Xolair

Popular Filters

Novartis presents strong new Ph III results with omalizumab in CSU

Novartis presents strong new Ph III results with omalizumab in CSU

05-10-2013

Novartis has presented new results from the Phase III ASTERIA I study showing omalizumab was effective…

DermatologicalsGenentechNovartisOmalizumabPharmaceuticalResearchXolair

UK's NICE approves NHS funding for Novartis' Xolair for all eligible patients

24-07-2013

The UK's drugs watch dog the National Institute for Health and Care Excellence (NICE) has stipulated…

EuropeHealthcareNovartisPharmaceuticalRespiratory and PulmonaryXolair

NICE makes U-turn, recommending Novartis' Xolair for children aged six-11 years

07-03-2013

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) has today (March 7)…

EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Genentech Ph III study of omalizumab shows promise in CIU

25-02-2013

Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase…

BiotechnologyDermatologicalsGenentechNovartisOmalizumabPharmaceuticalRegulationResearchRespiratory and PulmonaryRocheXolair

UK's NICE revokes NHS use of Novartis' Xolair for asthma in children and adults

09-11-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in draft guidance…

EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Back to top